Many 'social equity’ applicants priced out of cannabis store licenses – News 12 Connecticut

Connecticut will soon give out the first licenses for retail marijuana dispensaries, but many applicants say big money is pricing them out of the process.

Aprelle Mintz is one of them. She grew up in Bridgeport and wants to invest in her hometown.

„When you come down this side of Fairfield Avenue, it’s like the businesses stop,” she said.

Mintz, along with partners Jason Freeman and Anthony Robustelli, want to re-paint the picture of poverty in the Park City.

„We want to open a cannabis retail shop,” she said.

„It’s very competitive, to say the least,” said Freeman.

How competitive? The Connecticut Department of Consumer Protection received 8,360 applications for just six social equity licenses. Those licenses are set aside for people with ties to distressed communities, with strict income and residency requirements. The law requires a social equity applicant to own at least 65% of the business.

So why did so many applications come in? Entrants can submit as many times as they can afford. Just like the regular lottery, the more tickets you buy, the better your odds of winning. Some social equity ventures partnered with wealthy, out-of-state backers to submit dozens – even hundreds – of applications.

„This was not intended, but there was this loophole created,” said Andrea Comer, the chair of Connecticut’s Social Equity Council. „I am hopeful that the legislators will address that loophole going forward. But that said, this genie is already out of the bottle.”

Applications cost $250 dollars each. AJAM could only afford 10 of them.

„I’ve known people who took their savings just to do this whole process,” said Mintz. „They went broke thinking that they really had a chance, you know? And that’s how it was portrayed. That’s how it was given to us.”

DCP randomly selected the six applications earlier this week. Now the Social Equity Council must vet their paperwork before announcing the winners.

„We don’t want any social equity applicant to be a front for a larger company,” said Comer. „I’m hopeful that some of those multi-state operators, or all of them, are entering into this state with the same goal in mind, which is equity.”

If AJAM doesn’t get one of the six social equity slots, they’ll be automatically added to the traditional lottery. But those are long odds too. Connecticut is only awarding six licenses to non-equity ventures, and more than 7,000 applicants are already in the pool.

There will be more chances. DCP plans to hold multiple rounds of retail lotteries, depending on market factors and cannabis supply. But entrants like AJAM will have to pay the $250 per application fee all over again.

Still, just like her hometown, Mintz hopes to beat the odds.

„Our downtown is one block long. Everything closes at 8 at night,” she said. „We can make it live again and happening.”

Major uptick reported in cannabis vaping for all adolescents: Largest increases found among high-school seniors, tripling in 2 years from 5 to 14 percent – Science Daily

Cannabis vaping is increasing as the most popular method of cannabis delivery among all adolescents in the U.S., as is the frequency of cannabis vaping, according to research at Columbia University Mailman School of Public Health. The study found that the frequency of vaping cannabis among adolescents from all demographic groups is reported at six or more times per month, and rising faster than occasional use. Those who vape and smoke nicotine are more than 40 times more likely to also vape and smoke cannabis.

Until now time trends in vaping use had largely been unexamined including trends in use frequency, emerging disparities, and co-occurring use of other substances, which are all critical for surveillance and public health programmatic efforts. The findings are published in the journal Addiction.

„Heavy and frequent use of cannabis is increasing among U.S. adolescents, and vaped systems for products for both cannabis and nicotine are growing in number so understanding the prevalence and patterns of frequent cannabis vaping is important public health information for prevention,” said Katherine Keyes, PhD, professor of epidemiology at Columbia Mailman School. „Given rising concerns about cannabis vaping in terms of safety, and potential for transition to cannabis use disorder especially at frequent levels of use, these results indicate a necessity for public health intervention and increased regulation.”

The findings are based on the U.S.-based representative annual survey, Monitoring the Future, a population of 51,052 school-attending adolescents. Schools were randomly selected and invited to participate for two years.

Past 30-day frequent cannabis use with vaping increased (2.1 percent to 5.4 percent), while occasional use with vaping rose from 1.2 to 3.5 percent from 2017 to 2019. Past 30-day frequent (3.8 to 2.1 percent) and occasional (6.9 to 4.4 percent) cannabis use without vaping declined. Certain groups, such as Hispanic/Latino or lower socioeconomic status adolescents, experienced particularly notable increases in frequent cannabis use with vaping (e.g., prevalence among Hispanic/Latino adolescents in 2017: 2.2 percent, 2019: 6.7 percent)

According to Keyes, tobacco use and e-cigarettes, as well as binge drinking, are strongly linked to frequent cannabis use — both vaping and non-vaping. The evidence indicates that young adults who use nicotine, especially through vaporizers, are more likely to subsequently use vaped cannabis.

In fact, adolescents who reported smoking and vaping nicotine on more than 10 occasions of binge drinking, were 42 times and 10 times more likely to report past 30-day cannabis use with vaping, respectively, compared to no use.

„Given that it is easier for adolescents to conceal vaping than cannabis smoking, this mode of cannabis use may facilitate more frequent use,” comments Keyes.

Prevalence increased across grades, with the largest burden among high school seniors for whom past-30-day prevalence almost tripled from 5 percent (2017) to 14 percent (2019). The one-year increase in this grade from 2018 to 2019 (7.5 percent to 14 percent) is the second largest one-year increase in any type of substance use prevalence ever tracked by Monitoring the Future.

„This persisting prevalence of daily cannabis use, which in 2020 use was higher than any year since 1981, is of further alarm for several reasons, observes Keyes. „Heavy levels of cannabis use are associated with adverse cognitive and social outcomes for youth, as well as long-term trajectories of drug use that may have adverse health and other consequences.”

Also concerning is that high levels of tetrahydrocannabinol (THC) can be delivered through vaping devices, which may lead to dangerous consequences for youth users with lower tolerance.

„In addition, of note, is the evidence that the increases we are seeing in vaping as compared with smoking are concentrated among non-Hispanic white and higher socioeconomic status adolescents, the latter possibly reflecting the higher price point for vaping devices compared with other administration methods, „noted Keyes.

„As cannabis legalization continues across U.S. states, and as products, delivery systems, potency and marketing proliferate within a for-profit industry, increased attention to youth trends, including investment in sustained and evidence-based prevention and intervention, is increasingly urgent.”

Co-authors are Noah Kreski, Hadley Ankrum, Deborah Hasin, Silvia Martins, Mark Olfson, and Qixuan Chen, Columbia Mailman School; Magdalena Cerdá, New York University Grossman School of Medicine; and Richard Miech, University of Michigan.

The study was supported by National Center for Injury Prevention and Control, grant R49-CE003094; National Institute on Drug Abuse, grants R01DA001411, R01DA016575, R01DA037866, R01DA048853, R01DA048860.

FDA Head Admits Agency Has Been Slow To Regulate CBD, But Suggests Congress Needs To Do More – Marijuana Moment

Speaking to a congressional panel on Thursday, the head of the Food and Drug Administration (FDA) acknowledged that his agency has taken little regulatory action on CBD products in recent years despite the federal legalization of hemp and its derivatives.

“It looks pretty much the same in terms of where we are now,” FDA Commissioner Dr. Robert M. Califf told a House Appropriations subcommittee during a hearing that touched on CBD regulation, the nationwide shortage of baby formula and the therapeutic use of the plant kratom. “We just know more because we’ve done more research.”

The bulk of FDA funds spent on cannabidiol so far “has been spent on research to figure out what the risks, if any, are of various uses of this material in its different forms,” Califf said, adding that “the amazing plethora derivatives of the cannabis plant [are] surely quite profound and astounding and already in widespread use for a variety of means.”

But while Califf insisted he wants FDA to continue moving forward on rules for CBD products, he said the agency likely needs broader regulatory powers from Congress to get it done.

“I don’t think the current authorities we have on the food side or the drug side necessarily give us what we need to have to get the right pathways forward,” the commissioner said. “We’re going to have to come up with something new. I’m very committed to doing that.”

Califf was responding to questions from Rep. Dan Newhouse (R-WA), who noted that the lack of FDA regulations on CBD and other hemp-derived food and nutrition products has caused confusion across the country. “I believe we’re still waiting on FDA for some action to be taken,” Newhouse said. “Currently the industry is in a state of uncertainty because of no direction.”

Rep. Mark Pocan (D-WI) pressed the FDA commissioner further. “Technically CBD’s sale, in the eyes of the FDA, is illegal,” he said. “What is FDA’s plan to clarify that CBD could possibly be regulated as a food or food additive, and is there any timeline?”

“The research so far has shown that there are some risks with CBD, so we’re going to need a different pathway than just the standard pathway,” replied Califf, who previously served as FDA commissioner under President Barack Obama in 2016 and 2017. “You know, when you come six years later to the job you had before and nothing has really changed, that’s telling you that you can’t just keep trying to do the same thing over and over.”

Pocan also asked Califf about FDA’s position on the safety profile of kratom, a plant used as an alternative to opioids and as a tool to manage withdrawal symptoms. Pocan, who has regularly spoken favorably about kratom’s use as an opioid alternative, called FDA’s position on the drug “extremely antiquated.”

“You recently put more import alerts on companies that are doing a legal, proper way of handling kratom coming into the country versus the companies that aren’t,” he charged.

Pocan told Califf the National Institute on Drug Abuse (NIDA) “is in a very different place than you are on kratom.” At an earlier hearing a week ago the congressman expressed appreciation to NIDA Director Nora Volkow for supporting research into kratom.

“I do look forward to coming back to you, hopefully in a couple of months, with very specific suggestions on what to do there,” Califf replied, adding that FDA still believes the plant carries risks.

“We do have real adverse side effects, I mean, real negative things that have happened to people,” he said. “NIDA is doing a lot of research—I’m very good friends with Nora Volkow, the head of NIDA—we’ll continue to work with NIDA, and we’ll go where the science tells us to go.”

The National Institutes of Health (NIH) recently hosted a meeting to explore the therapeutic potential of the “controversial tree,” with an expert providing an overview of the science of kratom and what role it could play in mitigating the opioid crisis.

Thursday’s hearing of the House Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration and Related Agencies is the latest example of officials at both the state and federal levels expressing frustration with FDA’s slow handling of the CBD regulatory process.

FDA has had repeatedly said it is exploring regulatory pathways to allow for CBD commerce, and bipartisan lawmakers have introduced legislation this session to force a change.

The agency was mandated under legislation enacted in 2019 to provide an update on its regulatory approach to CBD. It did so in 2020, saying at the time that FDA “is currently evaluating issuance of a risk-based enforcement policy that would provide greater transparency and clarity regarding factors FDA intends to take into account in prioritizing enforcement decisions.”

Earlier this month, Rep. James Comer (R-KY), ranking member of the House Oversight and Reform Committee, called on congressional leadership to hold a standalone hearing to hold FDA accountable for its inaction on CBD and delta-8 THC products.

Comer said in a letter to Chairwoman Carolyn Maloney (D-NY) that purpose of the meeting should be to “examine the failure of [FDA] to develop a regulatory regime that effectively oversees the sale of hemp-derived extracts such as cannabidiol (CBD).”

While the GOP congressman seemed to be supporting regulations that would correct issues on mislabeling and contamination of CBD products, he also brought up the fact that companies are increasingly marketing items containing delta-8 THC, an intoxicating cannabinoid commonly synthesized using CBD that falls into an especially gray legal area because, unlike delta-9 THC, it’s not expressly prohibited under federal law.

While FDA has taken steps to issue warnings against select CBD and delta-8 THC companies that are peddling products with allegedly misleading medical claims, the agency has yet to implement specific marketing regulations for the cannabinoids.

Califf himself hasn’t been especially vocal about marijuana issues in general. But at a 2016 federally hosted research summit on cannabis, he recognized various therapeutic applications for the plant and its components, emphasizing at the time that the agency was interested in promoting research and development.

He also said that he’s personally prescribed a cannabinoid drug as a doctor.

Jonathan Miller, general council for the U.S. Hemp Roundtable, an industry group, told Marijuana Moment in a statement that he appreciated Califf’s responses at Thursday’s hearing.

“I’m quite encouraged by the tone of Commissioner Califf’s remarks—his frustration that nothing has been accomplished by the agency in the six years since he last served in that position, as well as his repeated commitment to identify pathways for CBD,” Miller said. “He’s looking for a creative approach, and the U.S. Hemp Roundtable looks forward to working with FDA on this. We will be reaching out in the days ahead to offer what we believe should be the first steps in this process.”

Sarah Chase, executive director of the Council for Federal Cannabis Regulation (CFCR), told Marijuana Moment that she was cautiously optimistic following Califf’s comments.

(Disclosure: Chase supports Marijuana Moment’s work through a monthly pledge on Patreon.)

“We were heartened to hear that he called for ‘creativity’ in moving cannabis reulation forward and that the agency is exploring a variety of pathways,” Chase said, adding that she hopes regulations are inclusive and “allow for a variety of industry to continue to thrive.”

CFCR is urging immediate congressional spending on FDA and the U.S. Department of Health and Human Services so officials can develop new, faster ways to evaluate compounds in cannabis, Chase said. “We call on Congress to ensure that the agency itself is adequately funded and staffed in order to do the work ahead.”

Congress Should Make It Easier For People To Get Pardons For Marijuana And Drug Convictions, Lawmakers Say At Hearing

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

This Siesta Key Company Makes Its Own CBD Products and Delta-8 – Sarasota


Marijuana is not legal for recreational use in the state of Florida. But there is another strain of THC sold in Florida that is legal, safe and produces similar effects. It’s called Delta-8 and Sarasotan Katie Sterling, owner of Siesta Key Sea Bee Dee, is making organic, pure-grade products out of it.

Sterling began making her own CBD tinctures five years ago after being prescribed painkillers to relieve her arthritis symptoms. A full-time mom and waitress for a number of years, she was in need of relief. She bought whole-flower hemp online and steeped it in Everclear—the old-school way to make CBD oil, she says.

„I didn’t turn back to painkillers again,” says Sterling. „I knew I had to share this with others.”

She started Siesta Key Sea Bee Dee two-and-a-half years ago, after receiving her hemp license from the Department of Agriculture. Under this license, Sterling can store, package and sell CBD and Delta-8 products online and in-person. She recently got another license that allows her to make ready-to-eat and solid foods–aka, edibles.

Now, she sells her lotions, tinctures, sprays and gummies at The Bazaar on Apricot & Lime, where she has her own massage room, wellness center and store. She’s always catching up on new cannabis guidelines and laws and has to renew her hemp license once per year. While the process can seem tedious, she finds it fascinating.

„I love talking to people about the different strains of THC and CBD and how they can help,” says Sterling. „There are so many options out there [there are over 100 strains of THC], but I think buying from a maker like myself can give you a more personalized experience than buying a vape or gummy from a gas station.”

Because of loopholes in federal law, the Delta-8 strain of THC found in the marijuana plant is legal. It can be ingested orally or topically, is less potent and produces a milder „high” without impairing you. Sterling says it can help with relief from pain, anxiety, insomnia and cramps, and that some people—even lifetime stoners—have come to prefer it over the traditional Delta-9 which surprisingly, Sterling can also sell.

But how?

„The legal limit for Delta-9 is 0.3 percent THC, so if any of the products you make contain less than that amount, you are good,” says Sterling. „This opens a lot of doors for people who may have tried CBD or Delta-8 for pain or anxiety, but didn’t feel any positive effects.”

So, if small amounts of the good old Delta-9 THC are legal, why was Delta-8 created? Sterling believes it was a way to skirt regulations. But now, lots of her customers prefer it.

„I call one of my Delta-8 products 'mommy’s little helper,’ because it works like a traditional Sativa strain, giving you energy,” she says. „Then we have another that’s a hybrid—25mg Delta-8 and 5mg CBD–and an Indica-style strain to help feel calm.”

CBD massage is located at Sterling's wellness center at The Bazaar on Apricot & Lime

As far as neew products, Sterling is always coming up with new ideas. She purchases all of her organic hemp from small farms in Oregon and Texas. Then she presses the plants into oil, infusing it into chocolates, gummies, lotion and sprays. She finds that the most difficult product to make is gummies, because of the humidity in Florida, but chocolates, on the other hand, are easier. So easy, in fact, she hosts monthly cooking classes with Cooking Mama 941 to show others how to make their own.

„That way, people who purchase marijuana using their cards can make their own edibles at home if they choose,” says Sterling. „People make them for 'pot parties’ instead of wine parties, now,” she says with a laugh.

If you’re just starting out with CBD, Sterling says the best product to try is a full-spectrum CBD with trace amounts of other cannabinoids. Then, if you want to take things up a notch, switch to Delta-8 or Delta-9 THC. Or, if you’re watching your sugar intake, try zero-sugar supplement drops in your water.

Sterling also recommends microdosing—a recent health phenomenon that involves taking very small doses of hallucinogens. This way, you don’t accidentally overmedicate–in other words, get too stoned.

„For years, I’ve seen the negative stigma of cannabis keep people from getting the natural relief they deserve. I’ve seen marijuana associated with illicit drugs in the fields of law and medicine,” says Sterling. „But I’ve known people who use CBD to assist recovery. It’s better than devastating outcomes we see all the time—accidental overdose of lethal substances like fentanyl.”

The narrative around CBD and marijuana is slowly shifting, even in Florida, in part to the legalization of medical marijuana programs across the state. This gives entrepreneurs like Sterling the opportunity to share their product and story of how cannabis helped them.

„It’s becoming more socially acceptable,” says Sterling. „I’ve gotten lots of positive feedback from the community and only hope to continue showing people love through my business.”

Find Siesta Key Sea Bee Dee products at The Bazaar on Apricot & Lime, 821 North Lime Ave., and at Dr. Melissa Harmon’s office of Integrative Wellness, 3443 Tamiami Trail #C, Port Charlotte. For more information or to purchase products online, click here or call (708) 254-1441.

DA says probe of vaping shops yields smoking materials stronger than legal hemp – Reading Eagle

In response to widespread complaints from parents about minors who have become sick after vaping or eating products labeled as containing hemp, undercover Berks County detectives went to vape-and-tobacco shops dotting the greater Reading metropolitan area to see if some of the products for sale were legal in Pennsylvania.

And many were not, with THC levels higher than the legal limit.

Hemp consists of the stem portion of the cannabis plant and, unlike marijuana, is not considered a controlled substance in Pennsylvania.

What the shops were selling, however, is not hemp, at least according to state regulation, Berks County District Attorney John T. Adams said in a press conference this afternoon announcing the results of the ongoing investigation by his Berks County Drug Task Force.

The task force received numerous complaints and tips regarding several vape/smoke shops in Berks selling illegal substances causing the users to become sick or intoxicated, Adams said. Some of the complaints came from the parents of minors who consumed these products.

The investigation revealed items marketed and sold as containing hemp or hemp derivatives do not meet the legal threshold standards established by the Pennsylvania Department of Agriculture.

To be classified as hemp under the Industrial Hemp Research Act, a product cannot contain more than 0.3% of a concentration of delta-9 tetrahydrocannabinol, also known as THC, the psychoactive ingredient in marijuana.

Any product containing a THC concentration greater than 0.3% or contains any other THC isomers is classified as a Schedule I controlled substance under the state’s Controlled Substance, Drug, Device and Cosmetic Act. The possession or distribution of such products is illegal.

The products tested all had limits over 0.3%.

As part of the Drug Task Force investigation, products such as vaping liquid, vegetable matter, and edibles were purchased and seized by undercover detectives from the establishments.

These products were marketed as Delta-8 and Delta-10, which is a Schedule I controlled substance, under the Controlled Substance, Drug, Device and Cosmetic Act. Detectives seized a total of approximately 1,700 products/units with an estimated total value of approximately $85,000.

Adams has decided that those in possession of or selling the products identified as containing a Schedule I controlled substance may choose to cooperate with law enforcement in lieu of criminal charges.

Cooperation includes the immediate surrender of the illegal products from the establishment and ceasing of any future sales of such products.

Detectives visited 14 shops and all the shops turned over the products. No charges were filed.

Should the sale of these products resume, he said, charges could be filed.

Additional penalties may be imposed for any subsequent offenses.

During this investigation, all store owners did cooperate with law enforcement, the DA said.

This story will be updated.

Clinical Trial: Topical CBD Ointment Efficacious for Psoriasis – Norml

Bangkok, Thailand: The topical application of an ointment containing 2.5 percent CBD improves symptoms of psoriasis, according to the findings of a randomized, placebo-controlled study published in the Journal of the European Academy of Dermatology and Venerology.

A team of investigators affiliated with King Chulalongkorn University Hospital and Thammasat University Hospital in Thailand assessed the twice daily application of either CBD or placebo over a 12-week period in 51 patients with mild plaque-type psoriasis. 

Areas treated with CBD showed significant improvements compared to areas treated with the placebo. Researchers did not identify any adverse effects attributable to the use of CBD.

“Our results indicated a trend of favorable response in the treatment with CBD, which has emerged as a therapeutic option for psoriasis,” authors concluded. “These outcomes will pave the way for future studies on [the] therapeutic effects of CBD.”

Prior studies have previously shown that CBD may reduce certain types of skin inflammation, including erythema, pruritis, and acne.

Full text of the study, “Topical cannabidiol-based treatment for psoriasis: A dual-centered randomized, placebo-controlled study,” appears in theJournal of the European Academy of Dermatology and Venerology.

Israeli cannabis industry grows with seeds export to US – Al-Monitor

Israel has exported cannabis seeds abroad for the first time ever. 

Israel’s Ministry of Agriculture said in a statement yesterday that seeds from the crop science company BetterSeeds were sent to the United States. There, they will be examined for marketability in the country, with more exports to follow. 

The Israeli government amended its medical cannabis export rules last year to allow for the export of cannabis seeds. The ministry is seeking to diversify its exports, boost domestic agriculture and expand the medical marijuana industry by exporting cannabis seeds, according to The Times of Israel

What is it? Cannabis seeds sprout into cannabis plants that produce the drug of the same name. Cannabis is often referred to as marijuana. 

BetterSeeds uses genetic editing technology to grow crops. The central Israel-based company’s purpose is to grow crops sustainably using less arable land.

Why it matters: Medical marijuana is a growing industry in Israel, and some companies have reported large profits recently. Marijuana for recreational use is fairly common in Israel as well. It is not legal, but has been somewhat decriminalized recently. There is increasing pressure to fully legalize the drug in Israel. 

Know more: Earlier this month, an Israeli company revealed a nasal spray that utilizes psychedelic mushrooms. Like cannabis, the mushrooms have the ability to treat a variety of ailments, including anxiety and post-traumatic stress disorder. 

NY Cannabis Control Board approves another 58 marijuana cultivators – syracuse.com

NY Cannabis Insider is hosting its first in-person conference in Albany on May 20th. The event will feature panel discussions led by industry experts, networking opportunities, lightning-round business consultations, a vendor fair and more. Tickets are available now.

New York’s Cannabis Control Board today approved another 58 growers to cultivate marijuana under conditional licenses, bringing the total number of licensed cultivators across the state to 146.

“We’re moving quickly, knowing that the growing season is short,” said Chris Alexander, head of the Office of Cannabis Management.

Conditional license holders can grow cannabis outdoors or in a greenhouse with up to 20 artificial lights. Provisional license holders will have to apply for full licenses by June 1, and the temporary licenses expire June 30, 2024.

Board member Adam Perry recused himself during Thursday’s meeting from voting on two licenses, the New York Seed Laboratory and Langdonhurst Farms.

During the 15-minute meeting, the board also discussed the social equity cannabis investment program, for which the agency is seeking a fund manager and design-build services.

Search our database below to see which cultivators have been issued a license.

Catching Up On Recent Cannabis Developments In New York State – – United States – Mondaq

To print this article, all you need is to be registered or login on Mondaq.com.

This is an exciting time in the adult-use marijuana space in New
York state – last month more than 80 small farmers received
conditional cultivator licenses. That means plants are going in the
ground, and recreational dispensaries will have product to sell
when they open later this year.

As things heat up, attorneys Heidi Schult Gregory and Meaghan
Feenan give our listeners a chance to get caught up on recent
cannabis developments, along with a look at what’s to come.
They address common questions such as what types of conditional
licenses are currently available and what makes them conditional?
Who is eligible for the various conditional licenses? How many will
be issued and what do they authorize?

Listen to the full episode below, and subscribe for
ongoing insights about the Cannabis market in New York state.

The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.

POPULAR ARTICLES ON: Cannabis & Hemp from United States

Successor Liability For Unpaid Taxes

Freeman Law

Generally, the purchaser of assets does not assume the liabilities of the seller. Successor liability, however, is an exception to the general rule. Under the successor-liability doctrine, …

Merger Control Comparative Guide

Talwar Thakore & Associates

Merger Control Comparative Guide for the jurisdiction of India, check out our comparative guides section to compare across multiple countries